Navigation Links
Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
Date:12/2/2008

Percentage of Biologic-Treated Psoriasis Patients Will Double by 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biologic agents, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will drive the moderate to severe psoriasis drug market to more than double to nearly $5 billion over the next decade.

The new Pharmacor report entitled Psoriasis finds that the overall psoriasis drug market will grow from $2.3 billion in 2007 to $5 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Following their launches by 2012, the uptake of Stelara and Abbott's ABT-874 will be particularly robust, owing to their novel mechanism of action, durable efficacy and infrequent administration. In 2017, Stelara and ABT-874 will capture 21 percent of sales in the moderate to severe psoriasis market.

Between 2007 and 2017, up to nine biologics will be available to treat psoriasis and the number of biologic-treated patients in the psoriasis market will grow significantly, according to the report. Among patients treated with a systemic drug therapy, the percentage of biologic-treated patients will double, growing from 23 percent in 2007 to 46 percent in 2017.

"With the recent launch of Humira and the highly anticipated launch of Stelara as early as December 2008, we expect a reshuffling to occur in the current order of first-line biologic agents for the treatment of psoriasis," said Joanna Kim, analyst at Decision Resources. "We forecast that Humira and Stelara will join Enbrel as first-line biologics for moderate to severe psoriasis by 2012."

About Decision Resources

Decision Resources (

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
2. CVS Caremark Applauds FTCs Leadership on Follow-on Biologics
3. Decision Resources White Paper Discusses Increasing Reality of Biosimilars and their Impact on Biologics Market
4. RTI Biologics Sees Expanded Surgeon User Base of Fresh OC Allografts
5. Biologics Dont Raise Cancer Risk in Rheumatoid Arthritis Patients
6. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
7. Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohns Disease
8. Science Fiction Has Become Reality with Remarkable Anti-Aging Treatment Breakthrough - Turning Back the Biological Clock in Aging
9. Children in Blended Families Still Close to Biological Mothers
10. Biological marker for Alzheimers holds promise for earlier diagnosis and treatment
11. Migraine mutations reveal clues to biological basis of disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... September 16, 2014 Advanced Fertility Center ... named by Houstonia Magazine as one of the Top ... Houstonia Magazine - a metropolitan magazine serving the Houston ... and recognize them for their outstanding services. This accomplishment ... edition of Houstonia Magazine — a special publication listing ...
(Date:9/16/2014)... Orlando, Florida (PRWEB) September 16, 2014 These ... the last 3 years to receive up to $10,000 in ... This program, as well as other state and federal programs, ... have to be paid back until you sell or move ... loan is a 0% interest loan. There are no monthly ...
(Date:9/16/2014)... Aspen Advisors, a U.S.-based healthcare IT consulting firm, ... high morale and collaborative culture in the ... Work For 2014.” Consulting magazine publishes the popular ... participating across all major industries, representing more than 350 ... firms were ranked in six categories - firm culture, ...
(Date:9/16/2014)... WASHINGTON, DC September 14, 2014 ... of everolimus-eluting stents (EES) and drug-eluting balloons ... drug-eluting stents found that EES provided superior ... outcomes. , Findings were reported today ... (TCT) scientific symposium. Sponsored by the Cardiovascular ...
(Date:9/16/2014)... absorbs the right balance of nitrogen, phosphorus and potassium ... Kansas State University study finds. , A review of ... and other regions showed that high yields were linked ... key nutrients at specific ratios - nitrogen and phosphorus ... at a ratio of 1-to-1. These nutrient uptake ratios ...
Breaking Medicine News(10 mins):Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3
... proteins CCSA-3 and CCSA-4, present in blood that accurately ... used to develop a blood test to identify ... a team of researchers led by Robert Getzenberg at ... proteins were first discovered by Getzenberg and colleagues at ...
... a tough task to answer who has the best pair of ... has pinned down the top ten beauties with the hottest legs. ... with the sexiest pair of legs, reports The Sun. ... the top slot. ,American R and B singer Beyonce ...
... socialite Paris Hilton has been getting a princess' treatment in ... to inmates, the 26-year-old is living in 'Lean Cuisine' style ... nuggets and fish that others would never get. ... of the women's jail in Lynwood, California, from a Los ...
... in daisy gravy, carnation and herb salad, nasturtium sauce -- ... the plate . ,"Flowers have been used for ... very secondary way", culinary historian Patrick Rambourg told AFP. "In ... the floor during banquets to perfume the room." , ...
... amended a law to ban circuses from importing or ... of animal rights, a legislator said Friday . ... Thursday, all imports and exports of animals such as ... are needed for research, said Tien Chiu-chin, of the ...
... links between alcohol, drugs and risky sexual behaviour are ... a government advisory body report said Friday . ... in the last 12 years, and media coverage of ... Independent Advisory Group on Sexual Health and HIV said. ...
Cached Medicine News:Health News:Flower-power on a Plate in Paris 2Health News:Drink and Drugs 'fuel British Sexual Health Crisis' 2
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... , Sept. 16, 2014 QPID Health , ... to new headquarters in Boston and ... headquarters will be at 175 Franklin Street in ... marketing teams. QPID Health,s new Southern California ... Carlsbad.  The expansion will help meet the demands of customers ...
(Date:9/16/2014)... , Sept. 16, 2014  Formex, ... manufacturing, announced that Mr. Greg Weilersbacher joined Formex ... 25, 2014. Greg Weilersbacher ... experience with focused expertise in Quality Assurance, ... Mr. Weilersbacher brings to Formex a ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... Amgen (Nasdaq: AMGN ) today announced ... had significantly greater adherence, compliance, and persistence during ... oral bisphosphonate commonly used to treat osteoporosis. ... compliance (a measure of how well patients follow ...
... March 23, 2011 NephRx Corporation today announced issuance ... novel growth factor peptide NX002 as a potential treatment ... NX002 may have applications in acute and chronic diseases ... colitis.  It has been shown to stimulate the growth ...
Cached Medicine Technology:Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 2Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 3Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 4Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 5Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 6Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 7Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 8Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 9Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 10Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate 11NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease 2
... reagent once reconstituted offers the laboratory all ... help maximize laboratory productivity, minimize operator error ... patented technology of the Infinity Urea (Nitrogen) ... and stability once reconstituted that will minimize ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
... Triglycerides powder reagent once reconstituted offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... powder reagent provides a long shelf ...
... Oxidase single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... Oxidase reagent provides a long shelf ...
Medicine Products: